Role of serum procalcitonin in the diagnosis and monitoring of treatment response in treatment-naïve subjects with chronic pulmonary aspergillosis

Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we inve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heliyon Jg. 9; H. 4; S. e15356
Hauptverfasser: Sehgal, Inderpaul Singh, Dhooria, Sahajal, Sachdeva, Naresh, Rudramurthy, Shivaprakash M., Prasad, Kuruswamy Thurai, Muthu, Valliappan, Aggarwal, Ashutosh Nath, Garg, Mandeep, Chakrabarti, Arunaloke, Agarwal, Ritesh
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Elsevier Ltd 01.04.2023
Elsevier
Schlagworte:
ISSN:2405-8440, 2405-8440
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA. We extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study’s primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy. We included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5–7.4%) and 100 (91.2–100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39–0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects. Plasma procalcitonin has poor performance in diagnosing and following subjects with CPA.
AbstractList Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA. We extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study’s primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy. We included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5–7.4%) and 100 (91.2–100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39–0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects. Plasma procalcitonin has poor performance in diagnosing and following subjects with CPA.
Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA. We extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study's primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy. We included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5-7.4%) and 100 (91.2-100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39-0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects. Plasma procalcitonin has poor performance in diagnosing and following subjects with CPA.
Background: Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA. Methods: We extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study’s primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy. Results: We included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5–7.4%) and 100 (91.2–100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39–0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects. Conclusion: Plasma procalcitonin has poor performance in diagnosing and following subjects with CPA.
Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA.BackgroundInterferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ levels. Thus, plasma PCT may be elevated in CPA and could have a role in diagnosing and monitoring treatment response in CPA. Herein, we investigate the diagnostic performance of plasma PCT in CPA.We extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study's primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy.MethodsWe extracted the demographic, clinical, radiological, treatment outcomes, and plasma PCT levels of CPA subjects and controls (previously treated pulmonary tuberculosis with radiological abnormalities on CT chest [diseased controls] and treatment naïve active pulmonary tuberculosis [PTB]). We treated CPA subjects with six months of oral itraconazole. We took 0.25 ng/mL as a cut-off value for PCT. The study's primary objective was to ascertain the diagnostic performance of PCT in diagnosing CPA. The key secondary outcome was to study the change in the plasma PCT levels after itraconazole therapy.We included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5-7.4%) and 100 (91.2-100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39-0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects.ResultsWe included 190 CPA cases and 40 controls (diseased controls [n = 20] and active PTB [n = 20]). PCT was elevated (≥0.25 ng/mL) in only 7 (3.7%) subjects with CPA. The sensitivity and specificity of PCT (≥0.25 ng/mL) were 3.7% (1.5-7.4%) and 100 (91.2-100%), respectively. The area under the curve for plasma PCT was 0.48 (95% confidence interval, 0.39-0.58). The plasma PCT values were available in 93 subjects at six months. There was a significant decline in the median plasma levels of PCT after treatment; however, the PCT levels either increased or remained the same in 45% of the subjects.Plasma procalcitonin has poor performance in diagnosing and following subjects with CPA.ConclusionPlasma procalcitonin has poor performance in diagnosing and following subjects with CPA.
ArticleNumber e15356
Author Dhooria, Sahajal
Aggarwal, Ashutosh Nath
Chakrabarti, Arunaloke
Prasad, Kuruswamy Thurai
Garg, Mandeep
Muthu, Valliappan
Agarwal, Ritesh
Sachdeva, Naresh
Rudramurthy, Shivaprakash M.
Sehgal, Inderpaul Singh
Author_xml – sequence: 1
  givenname: Inderpaul Singh
  orcidid: 0000-0002-6505-6019
  surname: Sehgal
  fullname: Sehgal, Inderpaul Singh
  email: inderpgi@outlook.com
  organization: Assistant Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 2
  givenname: Sahajal
  orcidid: 0000-0003-3199-9163
  surname: Dhooria
  fullname: Dhooria, Sahajal
  organization: Associate Professor, and Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 3
  givenname: Naresh
  orcidid: 0000-0001-6289-4749
  surname: Sachdeva
  fullname: Sachdeva, Naresh
  organization: Professor, Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 4
  givenname: Shivaprakash M.
  surname: Rudramurthy
  fullname: Rudramurthy, Shivaprakash M.
  organization: Professor, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 5
  givenname: Kuruswamy Thurai
  surname: Prasad
  fullname: Prasad, Kuruswamy Thurai
  organization: Assistant Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 6
  givenname: Valliappan
  surname: Muthu
  fullname: Muthu, Valliappan
  organization: Assistant Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 7
  givenname: Ashutosh Nath
  surname: Aggarwal
  fullname: Aggarwal, Ashutosh Nath
  organization: Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 8
  givenname: Mandeep
  surname: Garg
  fullname: Garg, Mandeep
  organization: Professor, Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
– sequence: 9
  givenname: Arunaloke
  orcidid: 0000-0003-1555-3807
  surname: Chakrabarti
  fullname: Chakrabarti, Arunaloke
  organization: Director, Doodhadhari Burfani Hospital, Haridwar, Uttarakhand, India
– sequence: 10
  givenname: Ritesh
  orcidid: 0000-0003-2547-7668
  surname: Agarwal
  fullname: Agarwal, Ritesh
  organization: Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37123983$$D View this record in MEDLINE/PubMed
BookMark eNqNUttqFDEYHqRia-0jKLn0Ztcc5pDBC5HioVAQRK9DkvlnNksmGZPMlj6HD-JD-GJmurvSelMhMCH5TpP_e16cOO-gKF4SvCaY1G-26w1Yc-vdmmLK1kAqVtVPijNa4mrFyxKf3NufFhcxbjHGpOJ127BnxSlrCGUtZ2fFz6_eAvI9ihDmEU3Ba2m1Sd4Zh_JKG0CdkYPz0UQkXYfGfJV8MG5YaCmATCO4hALEybsId6zj6crJ3792gOKstqBTRDcmbZDehCyi0TTbrCbDLZJxgjAYaxebF8XTXtoIF4fvefH944dvl59X118-XV2-v17pqm7SSklCekWZKlvOZdPUrAXeM0naTuuKlJhnAG9q6DDXGBihWLE2P0NbYalUz86Lq71u5-VWTMGMOYrw0oi7Ax8GIUMy2oIgSmsCrKR1qcpspKjClEvFZKdINs1a7_Za06xG6HT-9yDtA9GHN85sxOB3Is-TsaZqssLrg0LwP2aISYwmarBWOvBzFJRn-4bwmv0HFHNKSl4u0Ff3c_0NdGxABrzdA3TwMQboRZ6-TMYvMY3N-ZaItdiKQ-XEUjmxr1xmV_-wjwaP8Q7PBXm-OwNBRG3AaehMyD3JAzCPKPwBfKH4lg
CitedBy_id crossref_primary_10_1007_s11046_023_00751_z
crossref_primary_10_3389_fcimb_2024_1294971
crossref_primary_10_1093_infdis_jiae409
crossref_primary_10_1111_myc_13746
crossref_primary_10_1111_myc_70002
crossref_primary_10_3390_jof9111084
crossref_primary_10_1111_myc_70107
Cites_doi 10.1136/thoraxjnl-2020-216464
10.1183/13993003.00583-2015
10.1111/myc.12815
10.1016/j.ijregi.2022.11.005
10.1136/thoraxjnl-2019-213606
10.1016/0140-6736(93)90277-N
10.1111/myc.12987
10.1183/09031936.00011910
10.1093/infdis/jiab583
10.1016/j.jinf.2015.11.003
10.1111/myc.13324
10.1371/journal.pone.0114745
10.1016/S1473-3099(17)30592-3
10.1016/j.diagmicrobio.2013.04.023
10.5588/ijtld.17.0060
10.1080/17476348.2020.1750956
10.1016/j.jaip.2018.08.034
10.1186/s12890-017-0500-9
10.1016/S0140-6736(07)61602-X
10.1016/S1473-3099(22)00057-3
10.1128/JCM.01821-18
10.5588/ijtld.21.0034
10.1016/j.cmi.2019.01.007
ContentType Journal Article
Copyright 2023 The Authors
2023 The Authors.
2023 The Authors 2023
Copyright_xml – notice: 2023 The Authors
– notice: 2023 The Authors.
– notice: 2023 The Authors 2023
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
7S9
L.6
5PM
DOA
DOI 10.1016/j.heliyon.2023.e15356
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
PubMed
AGRICOLA

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2405-8440
ExternalDocumentID oai_doaj_org_article_1bcc1e34264b4639b2b028ab3adb18f3
PMC10133757
37123983
10_1016_j_heliyon_2023_e15356
S240584402302563X
Genre Journal Article
GroupedDBID 0R~
457
53G
5VS
6I.
AAEDW
AAFTH
AAFWJ
AALRI
AAYWO
ABMAC
ACGFS
ACLIJ
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEUPX
AEXQZ
AFJKZ
AFPKN
AFPUW
AFTJW
AGHFR
AIGII
AITUG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APXCP
BAWUL
BCNDV
DIK
EBS
EJD
FDB
GROUPED_DOAJ
HYE
IPNFZ
KQ8
M~E
O9-
OK1
RIG
ROL
RPM
SSZ
AAYXX
CITATION
0SF
AACTN
NCXOZ
NPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c567t-ba11fb23b4988a77639e8f3a19dcc51408a11876ed08c0e3120b39001950abbf3
IEDL.DBID DOA
ISICitedReferencesCount 8
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000999854600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2405-8440
IngestDate Fri Oct 03 12:51:16 EDT 2025
Thu Aug 21 18:37:45 EDT 2025
Fri Aug 22 20:24:27 EDT 2025
Fri Jul 11 15:58:09 EDT 2025
Thu Jan 02 22:52:53 EST 2025
Tue Nov 18 21:22:37 EST 2025
Sat Nov 29 07:32:59 EST 2025
Sat Oct 11 16:50:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Pneumonia
CFPA
CCPA
Pulmonary tuberculosis
Aspergilloma
Language English
License This is an open access article under the CC BY-NC-ND license.
2023 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c567t-ba11fb23b4988a77639e8f3a19dcc51408a11876ed08c0e3120b39001950abbf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6289-4749
0000-0003-3199-9163
0000-0003-2547-7668
0000-0002-6505-6019
0000-0003-1555-3807
OpenAccessLink https://doaj.org/article/1bcc1e34264b4639b2b028ab3adb18f3
PMID 37123983
PQID 2808214843
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_1bcc1e34264b4639b2b028ab3adb18f3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10133757
proquest_miscellaneous_2834271863
proquest_miscellaneous_2808214843
pubmed_primary_37123983
crossref_citationtrail_10_1016_j_heliyon_2023_e15356
crossref_primary_10_1016_j_heliyon_2023_e15356
elsevier_sciencedirect_doi_10_1016_j_heliyon_2023_e15356
PublicationCentury 2000
PublicationDate 2023-04-01
PublicationDateYYYYMMDD 2023-04-01
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Heliyon
PublicationTitleAlternate Heliyon
PublicationYear 2023
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Denning, Cole, Ray (bib3) 2023; 6
Sehgal (bib25) 2020; 6
Dou, Du, Liu, Shong (bib18) 2013; 76
Sehgal (bib1) 2019; 62
Tonkin-Crine (bib26) 2017; 9
Assicot (bib16) 1993; 341
Setianingrum (bib14) 2022; 77
Sehgal (bib8) 2019; 57
Sehgal (bib10) 2019; 7
Sehgal (bib7) 2021
Kwizera (bib15) 2017; 17
Monk (bib21) 2020
Sehgal, Dhooria, Muthu, Prasad, Agarwal (bib5) 2020; 14
von Elm (bib24) 2007; 370
Sehgal (bib9) 2019; 25
Oladele (bib13) 2017; 21
Agarwal, Denning, Chakrabarti (bib4) 2014; 9
Ugajin (bib20) 2011; 37
Sehgal (bib6) 2022; 22
Maruna, Nedelníková, Gürlich (bib17) 2000; 49
Colombo (bib22) 2022; 225
Schuetz (bib27) 2018; 18
Page, Richardson, Denning (bib11) 2016; 72
Nyamande, Lalloo (bib19) 2006; 10
Denning (bib23) 2016; 47
Baluku, Nuwagira, Bongomin, Denning (bib12) 2021; 25
Sehgal (bib2) 2018; 61
Sehgal (10.1016/j.heliyon.2023.e15356_bib7) 2021
Sehgal (10.1016/j.heliyon.2023.e15356_bib5) 2020; 14
Sehgal (10.1016/j.heliyon.2023.e15356_bib25) 2020; 6
Sehgal (10.1016/j.heliyon.2023.e15356_bib1) 2019; 62
Monk (10.1016/j.heliyon.2023.e15356_bib21) 2020
Denning (10.1016/j.heliyon.2023.e15356_bib23) 2016; 47
Baluku (10.1016/j.heliyon.2023.e15356_bib12) 2021; 25
Oladele (10.1016/j.heliyon.2023.e15356_bib13) 2017; 21
Sehgal (10.1016/j.heliyon.2023.e15356_bib2) 2018; 61
Denning (10.1016/j.heliyon.2023.e15356_bib3) 2023; 6
Assicot (10.1016/j.heliyon.2023.e15356_bib16) 1993; 341
Sehgal (10.1016/j.heliyon.2023.e15356_bib6) 2022; 22
Dou (10.1016/j.heliyon.2023.e15356_bib18) 2013; 76
Schuetz (10.1016/j.heliyon.2023.e15356_bib27) 2018; 18
Sehgal (10.1016/j.heliyon.2023.e15356_bib10) 2019; 7
Tonkin-Crine (10.1016/j.heliyon.2023.e15356_bib26) 2017; 9
Nyamande (10.1016/j.heliyon.2023.e15356_bib19) 2006; 10
Maruna (10.1016/j.heliyon.2023.e15356_bib17) 2000; 49
Kwizera (10.1016/j.heliyon.2023.e15356_bib15) 2017; 17
von Elm (10.1016/j.heliyon.2023.e15356_bib24) 2007; 370
Sehgal (10.1016/j.heliyon.2023.e15356_bib9) 2019; 25
Colombo (10.1016/j.heliyon.2023.e15356_bib22) 2022; 225
Setianingrum (10.1016/j.heliyon.2023.e15356_bib14) 2022; 77
Ugajin (10.1016/j.heliyon.2023.e15356_bib20) 2011; 37
Agarwal (10.1016/j.heliyon.2023.e15356_bib4) 2014; 9
Sehgal (10.1016/j.heliyon.2023.e15356_bib8) 2019; 57
Page (10.1016/j.heliyon.2023.e15356_bib11) 2016; 72
References_xml – volume: 77
  start-page: 821
  year: 2022
  end-page: 828
  ident: bib14
  article-title: A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL)
  publication-title: Thorax
– volume: 9
  year: 2017
  ident: bib26
  article-title: Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews
  publication-title: Cochrane Database Syst. Rev.
– volume: 370
  start-page: 1453
  year: 2007
  end-page: 1457
  ident: bib24
  article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
  publication-title: Lancet
– volume: 62
  start-page: 1108
  year: 2019
  end-page: 1115
  ident: bib1
  article-title: Efficiency of A fumigatus-specific IgG and galactomannan testing in the diagnosis of simple aspergilloma
  publication-title: Mycoses
– year: 2021
  ident: bib7
  article-title: Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: systematic review and a network meta-analysis
  publication-title: Mycoses
– volume: 10
  start-page: 510
  year: 2006
  end-page: 515
  ident: bib19
  article-title: Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP
  publication-title: Int. J. Tubercul. Lung Dis.
– volume: 341
  start-page: 515
  year: 1993
  end-page: 518
  ident: bib16
  article-title: High serum procalcitonin concentrations in patients with sepsis and infection
  publication-title: Lancet
– volume: 47
  start-page: 45
  year: 2016
  end-page: 68
  ident: bib23
  article-title: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
  publication-title: Eur. Respir. J.
– volume: 7
  start-page: 969
  year: 2019
  end-page: 974
  ident: bib10
  article-title: Is there an overlap in immune response between allergic bronchopulmonary and chronic pulmonary aspergillosis?
  publication-title: J. Allergy Clin. Immunol. Pract.
– volume: 6
  year: 2020
  ident: bib25
  article-title: Prevalence of vitamin D deficiency in treatment-naive subjects with chronic pulmonary aspergillosis
  publication-title: J Fungi (Basel)
– volume: 72
  start-page: 240
  year: 2016
  end-page: 249
  ident: bib11
  article-title: Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)
  publication-title: J. Infect.
– volume: 21
  start-page: 1056
  year: 2017
  end-page: 1061
  ident: bib13
  article-title: Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians
  publication-title: Int. J. Tubercul. Lung Dis.
– volume: 25
  start-page: 1157 e1151
  year: 2019
  end-page: e1157 e1157
  ident: bib9
  article-title: Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers
  publication-title: Clin. Microbiol. Infect.
– volume: 14
  start-page: 715
  year: 2020
  end-page: 727
  ident: bib5
  article-title: An overview of the available treatments for chronic cavitary pulmonary aspergillosis
  publication-title: Expet Rev. Respir. Med.
– volume: 17
  start-page: 149
  year: 2017
  ident: bib15
  article-title: Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis
  publication-title: BMC Pulm. Med.
– volume: 9
  year: 2014
  ident: bib4
  article-title: Estimation of the burden of chronic and allergic pulmonary aspergillosis in India
  publication-title: PLoS One
– volume: 225
  start-page: 1822
  year: 2022
  end-page: 1831
  ident: bib22
  article-title: Defective interferon-gamma production is common in chronic pulmonary aspergillosis
  publication-title: J. Infect. Dis.
– volume: 49
  start-page: S57
  year: 2000
  end-page: S61
  ident: bib17
  article-title: Physiology and genetics of procalcitonin
  publication-title: Physiol. Res.
– volume: 37
  start-page: 371
  year: 2011
  end-page: 375
  ident: bib20
  article-title: Usefulness of serum procalcitonin levels in pulmonary tuberculosis
  publication-title: Eur. Respir. J.
– volume: 57
  year: 2019
  ident: bib8
  article-title: Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis
  publication-title: J. Clin. Microbiol.
– volume: 25
  start-page: 537
  year: 2021
  end-page: 546
  ident: bib12
  article-title: Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities
  publication-title: Int. J. Tubercul. Lung Dis.
– volume: 22
  start-page: 1052
  year: 2022
  end-page: 1061
  ident: bib6
  article-title: Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India
  publication-title: Lancet Infect. Dis.
– volume: 61
  start-page: 770
  year: 2018
  end-page: 776
  ident: bib2
  article-title: Diagnostic cut-off of Aspergillus fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis
  publication-title: Mycoses
– volume: 6
  start-page: 7
  year: 2023
  end-page: 14
  ident: bib3
  article-title: New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB - a revised burden for India
  publication-title: IJID Reg
– year: 2020
  ident: bib21
  article-title: Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission
  publication-title: Thorax
– volume: 18
  start-page: 95
  year: 2018
  end-page: 107
  ident: bib27
  article-title: Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
  publication-title: Lancet Infect. Dis.
– volume: 76
  start-page: 464
  year: 2013
  end-page: 469
  ident: bib18
  article-title: The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis
  publication-title: Diagn. Microbiol. Infect. Dis.
– volume: 77
  start-page: 821
  year: 2022
  ident: 10.1016/j.heliyon.2023.e15356_bib14
  article-title: A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL)
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2020-216464
– volume: 9
  year: 2017
  ident: 10.1016/j.heliyon.2023.e15356_bib26
  article-title: Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews
  publication-title: Cochrane Database Syst. Rev.
– volume: 47
  start-page: 45
  year: 2016
  ident: 10.1016/j.heliyon.2023.e15356_bib23
  article-title: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00583-2015
– volume: 61
  start-page: 770
  year: 2018
  ident: 10.1016/j.heliyon.2023.e15356_bib2
  article-title: Diagnostic cut-off of Aspergillus fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis
  publication-title: Mycoses
  doi: 10.1111/myc.12815
– volume: 6
  start-page: 7
  year: 2023
  ident: 10.1016/j.heliyon.2023.e15356_bib3
  article-title: New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB - a revised burden for India
  publication-title: IJID Reg
  doi: 10.1016/j.ijregi.2022.11.005
– year: 2020
  ident: 10.1016/j.heliyon.2023.e15356_bib21
  article-title: Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2019-213606
– volume: 341
  start-page: 515
  year: 1993
  ident: 10.1016/j.heliyon.2023.e15356_bib16
  article-title: High serum procalcitonin concentrations in patients with sepsis and infection
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)90277-N
– volume: 62
  start-page: 1108
  year: 2019
  ident: 10.1016/j.heliyon.2023.e15356_bib1
  article-title: Efficiency of A fumigatus-specific IgG and galactomannan testing in the diagnosis of simple aspergilloma
  publication-title: Mycoses
  doi: 10.1111/myc.12987
– volume: 37
  start-page: 371
  year: 2011
  ident: 10.1016/j.heliyon.2023.e15356_bib20
  article-title: Usefulness of serum procalcitonin levels in pulmonary tuberculosis
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00011910
– volume: 225
  start-page: 1822
  year: 2022
  ident: 10.1016/j.heliyon.2023.e15356_bib22
  article-title: Defective interferon-gamma production is common in chronic pulmonary aspergillosis
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiab583
– volume: 72
  start-page: 240
  year: 2016
  ident: 10.1016/j.heliyon.2023.e15356_bib11
  article-title: Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2015.11.003
– year: 2021
  ident: 10.1016/j.heliyon.2023.e15356_bib7
  article-title: Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: systematic review and a network meta-analysis
  publication-title: Mycoses
  doi: 10.1111/myc.13324
– volume: 9
  year: 2014
  ident: 10.1016/j.heliyon.2023.e15356_bib4
  article-title: Estimation of the burden of chronic and allergic pulmonary aspergillosis in India
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114745
– volume: 10
  start-page: 510
  year: 2006
  ident: 10.1016/j.heliyon.2023.e15356_bib19
  article-title: Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP
  publication-title: Int. J. Tubercul. Lung Dis.
– volume: 18
  start-page: 95
  year: 2018
  ident: 10.1016/j.heliyon.2023.e15356_bib27
  article-title: Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(17)30592-3
– volume: 49
  start-page: S57
  issue: 1
  year: 2000
  ident: 10.1016/j.heliyon.2023.e15356_bib17
  article-title: Physiology and genetics of procalcitonin
  publication-title: Physiol. Res.
– volume: 76
  start-page: 464
  year: 2013
  ident: 10.1016/j.heliyon.2023.e15356_bib18
  article-title: The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2013.04.023
– volume: 21
  start-page: 1056
  year: 2017
  ident: 10.1016/j.heliyon.2023.e15356_bib13
  article-title: Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians
  publication-title: Int. J. Tubercul. Lung Dis.
  doi: 10.5588/ijtld.17.0060
– volume: 6
  year: 2020
  ident: 10.1016/j.heliyon.2023.e15356_bib25
  article-title: Prevalence of vitamin D deficiency in treatment-naive subjects with chronic pulmonary aspergillosis
  publication-title: J Fungi (Basel)
– volume: 14
  start-page: 715
  year: 2020
  ident: 10.1016/j.heliyon.2023.e15356_bib5
  article-title: An overview of the available treatments for chronic cavitary pulmonary aspergillosis
  publication-title: Expet Rev. Respir. Med.
  doi: 10.1080/17476348.2020.1750956
– volume: 7
  start-page: 969
  year: 2019
  ident: 10.1016/j.heliyon.2023.e15356_bib10
  article-title: Is there an overlap in immune response between allergic bronchopulmonary and chronic pulmonary aspergillosis?
  publication-title: J. Allergy Clin. Immunol. Pract.
  doi: 10.1016/j.jaip.2018.08.034
– volume: 17
  start-page: 149
  year: 2017
  ident: 10.1016/j.heliyon.2023.e15356_bib15
  article-title: Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis
  publication-title: BMC Pulm. Med.
  doi: 10.1186/s12890-017-0500-9
– volume: 370
  start-page: 1453
  year: 2007
  ident: 10.1016/j.heliyon.2023.e15356_bib24
  article-title: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)61602-X
– volume: 22
  start-page: 1052
  year: 2022
  ident: 10.1016/j.heliyon.2023.e15356_bib6
  article-title: Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(22)00057-3
– volume: 57
  year: 2019
  ident: 10.1016/j.heliyon.2023.e15356_bib8
  article-title: Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis
  publication-title: J. Clin. Microbiol.
  doi: 10.1128/JCM.01821-18
– volume: 25
  start-page: 537
  year: 2021
  ident: 10.1016/j.heliyon.2023.e15356_bib12
  article-title: Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities
  publication-title: Int. J. Tubercul. Lung Dis.
  doi: 10.5588/ijtld.21.0034
– volume: 25
  start-page: 1157 e1151
  year: 2019
  ident: 10.1016/j.heliyon.2023.e15356_bib9
  article-title: Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2019.01.007
SSID ssj0001586973
Score 2.2760313
Snippet Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated with low IFN-γ...
Background: Interferon-gamma (IFN-γ) down-regulates plasma procalcitonin (PCT), marker of inflammation. Chronic pulmonary aspergillosis (CPA) is associated...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e15356
SubjectTerms Aspergilloma
aspergillosis
blood serum
CCPA
CFPA
chest
confidence interval
inflammation
interferon-gamma
itraconazole
Pneumonia
Pulmonary tuberculosis
therapeutics
tuberculosis
Title Role of serum procalcitonin in the diagnosis and monitoring of treatment response in treatment-naïve subjects with chronic pulmonary aspergillosis
URI https://dx.doi.org/10.1016/j.heliyon.2023.e15356
https://www.ncbi.nlm.nih.gov/pubmed/37123983
https://www.proquest.com/docview/2808214843
https://www.proquest.com/docview/2834271863
https://pubmed.ncbi.nlm.nih.gov/PMC10133757
https://doaj.org/article/1bcc1e34264b4639b2b028ab3adb18f3
Volume 9
WOSCitedRecordID wos000999854600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Open Access Full Text
  customDbUrl:
  eissn: 2405-8440
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586973
  issn: 2405-8440
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2405-8440
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001586973
  issn: 2405-8440
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELagQogLKr_dFiojcc02ib2JfQTUiksrhEDam2U7Dk2VJtVmU6kXXqIP0ofoizFjJ8suSOwFabWHxI5_ZibfxB5_Q8h7LrXL4OUYFSLhEWdlEQEKigigFxTK2dgy65NN5GdnYj6XX9ZSfWFMWKAHDhN3lBhrE8cQuA0HODWpAUjUhunCJKL0PJ_g9ax9TIXzwSKTfnsZEGsWCWj59_Gdo4vpuaurmxb5T1M2dWD1mMB6DZg8f_8GPv3tf_4ZRrmGSye75OngUNIPYSDPyAPXPCePT4ct8xfk9mtbO9qWFHStv6QIWLq2YMdN1VD4gQNIixBvV3VUNwW99GaO631YbRWJThchnNb5WuPVqNH3d9eOdr3BFZ2O4sIutYFyl171NTxNL26oRkbyH1VdYzMvyfeT42-fPkdDJobIzrJ8GRmdJKVJmeFSCJ3DO0k6mHudyMJacLlioTFteeaKWNjYsSSNDZP-MGKsjSnZK7LTtI3bI5SXspDIScO448YZwfXMZgW4YRK55NmE8FEMyg405Zgto1ZjPNqFGqSnUHoqSG9CpqtqV4GnY1uFjyjjVWGk2fYXQPnUoHxqm_JNiBg1RA0eS_BE4FHVtvbfjRqlwKJxm0Y3ru07lQpwy-ArlbN_lYFOgVuRQZnXQQtXI2F5gqSO2LkN_dwY6uadpjr3zOLQXcbyWb7_PybngDzB8YYwpzdkZ7no3VvyyF4vq25xSB7mc3HorRb-T38e_wLLw0su
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+serum+procalcitonin+in+the+diagnosis+and+monitoring+of+treatment+response+in+treatment-na%C3%AFve+subjects+with+chronic+pulmonary+aspergillosis&rft.jtitle=Heliyon&rft.au=Sehgal%2C+Inderpaul+Singh&rft.au=Dhooria%2C+Sahajal&rft.au=Sachdeva%2C+Naresh&rft.au=Rudramurthy%2C+Shivaprakash+M.&rft.date=2023-04-01&rft.pub=Elsevier+Ltd&rft.issn=2405-8440&rft.eissn=2405-8440&rft.volume=9&rft.issue=4&rft_id=info:doi/10.1016%2Fj.heliyon.2023.e15356&rft.externalDocID=S240584402302563X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-8440&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-8440&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-8440&client=summon